Cardiol Therapeutics Advances CRD-38 Toward Clinical Trials Following Landmark Research Publication
Cardiol Therapeutics has taken a major step forward in advancing CRD-38, its subcutaneous cannabidiol-based drug candidate, with the publication of groundbreaking research in the Journal of the American College of Cardiology: Basic to Translational Science.
The study provides key evidence that CRD-38 reduces heart failure progression through mitochondrial preservation and anti-inflammatory mechanisms. Read more...

Cardiol Therapeutics: Advancing Care for Pericarditis Patients 🌟
Cardiol Therapeutics is revolutionizing care for pericarditis, a challenging inflammatory heart condition. Their flagship therapy, CardiolRx™, targets inflammation to improve outcomes and reduce recurrences. Read more...

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL): Positioned for Market-Driven Growth
With the biotech sector experiencing a resurgence, Cardiol Therapeutics is strategically positioned for strong market-driven gains.
📌 Why Cardiol is a High-Value Stock to Watch
✅ Undervalued Market Cap - Compared to competitors, Cardiol remains an under-the-radar biotech with significant upside potential.
✅ Upcoming Growth Catalysts - Clinical trial results, FDA milestones, and institutional interest provide strong momentum.
✅ Industry-Wide Tailwinds - Increased biotech R&D funding and favorable regulatory conditions enhance growth prospects.
✅ Investor-Friendly Market Position - With dual NASDAQ/TSX listings, Cardiol is accessible to both U.S. Read more...